Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A Ferrant is active.

Publication


Featured researches published by A Ferrant.


Oncology | 1993

Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma

I Sklenar; G Schiffman; Jønsson; Gregor Verhoef; H Birgens; Marc Boogaerts; A Ferrant; B E Christensen; H Hasle; A Drivsholm

Polyclonal intravenous IgG (IVIG) was administered as an infusion 6 times every 3 weeks (week 0, 3, 6, 9, 12, 15) in doses of 0.1, 0.4 and 0.8 g/kg BW to determine the dose causing an increase in 12 pneumococcal antibody types above the protective level of 200 ng/ml of antibody N. The dose of 0.4 g/kg BW was found to be optimal in patients with chronic lymphocytic leukaemia (CLL). From the first infusion onwards at least 80% of CLL patients had increases in all 12 antibodies. Five weeks after the last infusion the antibody levels were still elevated in 80% of patients with CLL. The dose of 0.8 g/kg raised all 12 antibodies in 53-73% of CLL patients when assessments were made after each infusion. In multiple myeloma (MM) patients, 73-82% and 73-91% of patients had increased antibody levels, respectively, before and after the 4th-6th infusions at the 0.8 g/kg dose level. However, in only 45-50% of patients did the antibodies remain increased 2 weeks after the treatment at this dose. The dose of 0.4 g/kg caused antibody increases in only 30-50% of patients when measured before the 4th-6th infusion. Serum IgG increased significantly only in the CLL patients, whereas in the MM patients it was high from the beginning owing to the disease. Therefore, the pneumococcal antibody levels were a better marker for the purpose of dose finding. The dosage recommendation in CLL is 0.4 g/kg every 3 weeks until week 12, when steady state is reached. The maintenance dose is 0.4 g/kg every 5 weeks. In MM patients, who have a faster elimination rate of antibodies, the recommended loading dose is 0.8 g/kg, followed by 0.4 g/kg every week as a continuous treatment. Treatment with IVIG in CLL and MM was generally well tolerated. Only 25% of patients experienced minor side-effects, the most frequent being febrile reactions, shivering and headache.


Leukemia | 2001

Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression.

Véronique Deneys; L Michaux; P Leveugle; Anne-Marie Mazzon; E Gillis; A Ferrant; Jean-Marie Scheiff; M De Bruyère

Integration of morphological and immunophenotypic data is critical in achieving diagnosis accuracy and minimising interobserver interpretative discrepancies. The aim of this work was to compare the immunophenotype and the morphology of chronic lymphocytic leukaemia and mantle cell lymphoma, to help in the differential diagnosis of CD5 positive monoclonal B cells. Frozen/thawed samples from 91 patients were analysed retrospectively. Fresh samples from 17 mixed/atypical CLL and 13 MCL were tested to corroborate the results. Markers were analysed as percentage (%) of positive B lymphocyte subpopulation, and in terms of median fluorescence intensity (MFI). Matutess CLL score clearly allowed distinguishing between classical CLL on the one hand, and atypical CLL and MCL on the other hand. The percentage of CD54-positive cells and the median fluorescence intensity of CD20 and CD54 were the only parameters which were significantly higher in MCL than in atypical CLL (P < 0.05), allowing an immunological distinction between these two entities. Nevertheless, due to a quenching problem when using CD20 and CD54 together, and because CD18 showed a statistically different expression between classical and atypical CLL, the combination of CD18/CD54 has been preferred and showed a different pattern in the three entities. Immunophenotyping could be helpful in the differential diagnosis of CD5-positive B cell chronic lymphoproliferative disorders with atypical features that do not fit exactly into any of the morphologic proposed groups.


Leukemia & Lymphoma | 1995

Cytogenetics of Hybrid Acute Leukemias

Antonio Cuneo; Marc Boogaerts; A Ferrant; Jean-Louis Michaux; André Bosly; Andre Louwagie; Herman Van den Berghe; Rosa Balsamo; Grazia Roberti; Antonella Bardi; Gianluigi Castoldi

Although the recognition of hybrid acute leukemia (HAL) is still controversial, several reports have described cytogenetic findings in these leukemias over the last 3 years. A distinct chromosomal profile appears to be associated with different immunologic subsets of HAL. The classical t(15;17), and inv(16) as well as abnormalities of the long arm of chromosome 5 and/or 7 are preferentially associated with acute myeloid leukemia (AML) with T-cell features; the t(8;21)(q22;q22), the Ph chromosome, and 11q23 rearrangements are more frequently found in AML with B-cell features; the Ph chromosome, t11q23 and 14q32 breaks without rearrangements of the immunoglobulin heavy chain gene may be associated with acute lymphoblastic leukemia (ALL) with myeloid markers. In addition, some chromosome aberrations may be encountered more frequently in acute leukemia with major phenotype deviations than in unselected cases of acute leukemia: namely the Ph chromosome, 11q23 rearrangements, and +13. These chromosome changes appear to be associated with a low complete remission (CR) rate. An association has been documented in some patients with ALL between the presence of the t(9;22) and a minor myeloid component consisting of 5-15% blast cells with myelomonocytic features, raising the possibility that a diagnosis of bilineal acute leukemia would be more appropriate in such cases. These patients appear to have a severe outcome with significantly lower CR rate than similar cases of Ph-positive ALL without a minor myeloid component.(ABSTRACT TRUNCATED AT 250 WORDS)


Blood | 1975

A new hematologic syndrome with a distinct karyotype: the 5 q-- chromosome

G. Sokal; Jl. Michaux; H. Van den Berghe; A Cordier; J. Rodhain; A Ferrant; Maurice Moriau; M De Bruyere; J. Sonnet


Haematologica | 1996

Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features.

Antonio Cuneo; A Ferrant; Jl. Michaux; H Demuynck; M. A. Boogaerts; A. Louwagie; Chantal Doyen; M. Stul; J.J. Cassiman; P. Dal Cin; G Castoldi; H Van den Berghe


Cancer Genetics and Cytogenetics | 1996

Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype : Study of nine cases

Antonio Cuneo; A Ferrant; Jean-Louis Michaux; André Bosly; Bernard Chatelain; Michel Stul; Paola Dal Cin; Judith Dierlamm; Jean-Jacques Cassiman; Dieter K. Hossfeld; Gianluigi Castoldi; Herman Van den Berghe


Acta Clinica Belgica | 2007

Rituximab therapy for immune-mediated hematological disorders: A Belgian multi-center project

Daan Dierickx; Ann Janssens; Gregor Verhoef; A Ferrant; P Minneur; Alina Ferster; B Deprijk; M Dresse; Dominique Boulet; Yves Beguin; Christiane Vermylen


Onkologie | 2010

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML

S Groeschel; Sanne Lugthart; Berna Beverloo; Sabine Kayser; S. L. Van Zelderen-Bhola; Gj Ossenkoppele; Edo Vellenga; E van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; A Ferrant; C-H Koehne; Michael Pfreundschuh; H-A Horst; Elisabeth Koller; M. von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F. Schlenk; Ruud Delwel; Konstanze Doehner; Bob Löwenberg; Hartmut Doehner


Archive | 2016

Syndrome With a Distinct Karyotype: The 5 q - Chromosome

G. Sokal; Jl. Michaux; H. Van Den Berghe; A Cordier; J. Rodham; A Ferrant; Maurice Moriau; J. Sonnet


Archive | 2011

chromosome A new hematologic syndrome with a distinct karyotype: the 5 q--

G. Sokal; H. Van den Berghe; A Cordier; J. Rodhain; A Ferrant; Maurice Moriau; M De Bruyere

Collaboration


Dive into the A Ferrant's collaboration.

Top Co-Authors

Avatar

Chantal Doyen

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

H Demuynck

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Marc Boogaerts

Catholic University of Leuven

View shared research outputs
Top Co-Authors

Avatar

J Maertens

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Lucienne Michaux

Catholic University of Leuven

View shared research outputs
Top Co-Authors

Avatar

D Bron

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Koen Theunissen

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Pierre Zachee

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Rik Schots

Vrije Universiteit Brussel

View shared research outputs
Top Co-Authors

Avatar

André Bosly

Université catholique de Louvain

View shared research outputs
Researchain Logo
Decentralizing Knowledge